Logo image of MIRA

MIRA PHARMACEUTICALS INC (MIRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MIRA - US60458C1045 - Common Stock

1.59 USD
+0.05 (+3.25%)
Last: 12/23/2025, 8:21:11 PM
1.55 USD
-0.04 (-2.52%)
After Hours: 12/23/2025, 8:21:11 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MIRA. MIRA was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for MIRA as it has an excellent financial health rating, but there are worries on the profitability. MIRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MIRA has reported negative net income.
MIRA had a negative operating cash flow in the past year.
In the past 5 years MIRA always reported negative net income.
In the past 5 years MIRA always reported negative operating cash flow.
MIRA Yearly Net Income VS EBIT VS OCF VS FCFMIRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

MIRA's Return On Assets of -372.26% is on the low side compared to the rest of the industry. MIRA is outperformed by 94.79% of its industry peers.
Looking at the Return On Equity, with a value of -376.40%, MIRA is doing worse than 77.60% of the companies in the same industry.
Industry RankSector Rank
ROA -372.26%
ROE -376.4%
ROIC N/A
ROA(3y)-444.7%
ROA(5y)-340.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MIRA Yearly ROA, ROE, ROICMIRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

MIRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIRA Yearly Profit, Operating, Gross MarginsMIRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, MIRA has more shares outstanding
There is no outstanding debt for MIRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MIRA Yearly Shares OutstandingMIRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
MIRA Yearly Total Debt VS Total AssetsMIRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

An Altman-Z score of 453.18 indicates that MIRA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 453.18, MIRA belongs to the best of the industry, outperforming 99.48% of the companies in the same industry.
MIRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 453.18
ROIC/WACCN/A
WACCN/A
MIRA Yearly LT Debt VS Equity VS FCFMIRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

2.3 Liquidity

MIRA has a Current Ratio of 90.56. This indicates that MIRA is financially healthy and has no problem in meeting its short term obligations.
MIRA's Current ratio of 90.56 is amongst the best of the industry. MIRA outperforms 100.00% of its industry peers.
MIRA has a Quick Ratio of 90.56. This indicates that MIRA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 90.56, MIRA belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 90.56
Quick Ratio 90.56
MIRA Yearly Current Assets VS Current LiabilitesMIRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

MIRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -108.59%.
EPS 1Y (TTM)-108.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MIRA will show a very strong growth in Earnings Per Share. The EPS will grow by 28.33% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-129.5%
EPS Next 2Y28.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MIRA Yearly EPS VS EstimatesMIRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MIRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MIRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRA Price Earnings VS Forward Price EarningsMIRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRA Per share dataMIRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

MIRA's earnings are expected to grow with 28.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.33%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MIRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MIRA PHARMACEUTICALS INC

NASDAQ:MIRA (12/23/2025, 8:21:11 PM)

After market: 1.55 -0.04 (-2.52%)

1.59

+0.05 (+3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)04-15 2026-04-15/bmo
Inst Owners3.25%
Inst Owner Change39.51%
Ins Owners10.59%
Ins Owner Change67.04%
Market Cap66.59M
Revenue(TTM)N/A
Net Income(TTM)-28.42M
Analysts82.86
Price Target3.06 (92.45%)
Short Float %0.78%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.3%
Min EPS beat(2)26.47%
Max EPS beat(2)32.13%
EPS beat(4)4
Avg EPS beat(4)30.41%
Min EPS beat(4)25.63%
Max EPS beat(4)37.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-83.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)-216.22%
EPS NY rev (3m)-216.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.82
P/tB 8.82
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -372.26%
ROE -376.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-444.7%
ROA(5y)-340.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 90.56
Quick Ratio 90.56
Altman-Z 453.18
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y-129.5%
EPS Next 2Y28.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.69%
OCF growth 3YN/A
OCF growth 5YN/A

MIRA PHARMACEUTICALS INC / MIRA FAQ

What is the ChartMill fundamental rating of MIRA PHARMACEUTICALS INC (MIRA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MIRA.


What is the valuation status for MIRA stock?

ChartMill assigns a valuation rating of 1 / 10 to MIRA PHARMACEUTICALS INC (MIRA). This can be considered as Overvalued.


What is the profitability of MIRA stock?

MIRA PHARMACEUTICALS INC (MIRA) has a profitability rating of 0 / 10.


Can you provide the financial health for MIRA stock?

The financial health rating of MIRA PHARMACEUTICALS INC (MIRA) is 8 / 10.